Renaissance Capital logo

ACRV News

Renaissance Capital's November IPO Market Update

ACRV

It was the IPO market's slowest November in six years as just four deals raised a combined $166 million. The month's lineup was led by $50+ million IPOs, biotech Acrivon Therapeutics (ACRV) and Chinese hotel chain Atour Lifestyle Holdings (ATAT). Two small issuers also slipped through the IPO window despite increased scrutiny from regulators....read more

US IPO Weekly Recap: Biotech Acrivon completes the week’s sole IPO while big deals join the pipeline

ACRV

After delaying its offering, Acrivon Therapeutics (ACRV) completed the week’s sole IPO. In the pipeline, seven companies submitted initial filings, including three planning to raise $100 million. Biotech Acrivon Therapeutics (ACRV) offered more shares and priced well below the range to raise $94 million at a $277 million market cap. The...read more

Oncology biotech Acrivon Therapeutics prices IPO at $12.50, well below the range

ACRV

Acrivon Therapeutics, a Phase 2 biotech developing proteomics-based precision oncology therapies, raised $94 million by offering 7.6 million shares at $12.50, well below the range of $16 to $18. The company offered 1.7 million more shares than anticipated, and prior to pricing, it had disclosed insider indications on 88% of shares in the offering. The company also raised an...read more

US IPO Week Ahead: IPO calendar quiets down after a relatively active week

MNX

After a relatively active week for the IPO market, the calendar is expected to quiet down again. One small deal is scheduled to price, though it is too small to be included in our IPO stats. Biotech Acrivon Therapeutics (ACRV) may also price, after delaying its $100 million IPO. Nano-cap BullFrog AI Holdings (BFAI) plans to raise $8 million at...read more